ArticleJournal of medicinal chemistry2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose-Ranging Study.Clinical and translational science · 2026Trial
- Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Nitrile-Based Inhibitors Targeting both SARS-CoV‑2 Main Protease and Human Cathepsin L.ACS medicinal chemistry letters · 2026Article
- Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.Molecules (Basel, Switzerland) · 2026Review
- Structure-based macrocyclization of α-ketoamides leads to potent inhibitors of coronaviral and enteroviral proteases.Communications chemistry · 2026Article
- Design, synthesis, and X-ray structural studies of potent SARS-CoV-2 Mpro inhibitors containing tetrahydroisoquinoline-3-carboxamides as P2 ligands.RSC medicinal chemistry · 2026Article
- Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Inhibitory effects and structural analysis of drug candidate PF-07817883 against coronaviral main proteases (MJournal of structural biology: X · 2026Article
- 9-fluorenone-based synthetic sulfonamide compounds as dual inhibitors of SARS-CoV-2 Main-Protease and Papain-like Protease.Molecular diversity · 2026Article
- Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Nature communications · 2026Article
- Inhibitors Targeting SARS-CoV-2 Papain-Like Protease: Screening, Design, Synthesis, and Biological Evaluation.ChemMedChem · 2026Article
- Cleavage at the nsp5-nsp6 site of SARS-CoV-2 main protease intermediate precursor is faster from a monomer than a dimer form.The Journal of biological chemistry · 2026Article
- Next-generation inhibitors of SARS-CoV-2 MNature communications · 2026Article
- Discovery of EGT710, an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease Inhibitor.Journal of medicinal chemistry · 2026Article
- Characterization of the Cross-Resistance of SARS-CoV‑2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir.ACS pharmacology & translational science · 2026Article
- Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors.Current issues in molecular biology · 2026Article
- Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models.Journal of medicinal chemistry · 2026Article
- Structure-guided discovery of a small molecule inhibitor of SARS-CoV-2 main protease with potentJournal of virology · 2025Article
- Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS-CoV-2 Mpro for Next-Generation PROTAC-Based Therapeutics.Archiv der Pharmazie · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Charlotte M N AllertonPfizer Research & Development, Cambridge, Massachusetts 02139, United States.
Joel T ArcariPfizer Research & Development, Groton, Connecticut 06340, United States.
Lisa M AschenbrennerPfizer Research & Development, Groton, Connecticut 06340, United States.
Melissa AveryPfizer Research & Development, Groton, Connecticut 06340, United States.
Bruce M BechlePfizer Research & Development, Groton, Connecticut 06340, United States.
Mohammad Amin BehzadiPfizer Research & Development, Pearl River, New York 10965, United States.
Britton BorasPfizer Research & Development, La Jolla, California 92121, United States.ORCID 0000-0003-3624-9177
Leanne M BuzonPfizer Research & Development, Groton, Connecticut 06340, United States.
Rhonda D CardinPfizer Research & Development, Pearl River, New York 10965, United States.
Natasha R CatlinPfizer Research & Development, Groton, Connecticut 06340, United States.
Anthony A CarloPfizer Research & Development, Groton, Connecticut 06340, United States.
Karen J CoffmanPfizer Research & Development, Groton, Connecticut 06340, United States.
Alyssa DantonioPfizer Research & Development, Groton, Connecticut 06340, United States.
Li DiPfizer Research & Development, Groton, Connecticut 06340, United States.ORCID 0000-0001-6117-9022
Heather EngPfizer Research & Development, Groton, Connecticut 06340, United States.
Kathleen A FarleyPfizer Research & Development, Groton, Connecticut 06340, United States.ORCID 0000-0001-8935-6852
Rose Ann FerrePfizer Research & Development, La Jolla, California 92121, United States.
Steven S GernhardtPfizer Research & Development, Groton, Connecticut 06340, United States.
Scott A GibsonInstitute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah 84322, United States.
Samantha E GreasleyPfizer Research & Development, La Jolla, California 92121, United States.
Siennah R GreenfieldPfizer Research & Development, Cambridge, Massachusetts 02139, United States.
Brett L HurstInstitute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah 84322, United States.
Amit S KalgutkarPfizer Research & Development, Cambridge, Massachusetts 02139, United States.ORCID 0000-0001-9701-756X
Emi KimotoPfizer Research & Development, Groton, Connecticut 06340, United States.ORCID 0000-0003-1284-2769
Lorraine F LanyonPfizer Research & Development, Groton, Connecticut 06340, United States.
Gabrielle H LovettPfizer Research & Development, Cambridge, Massachusetts 02139, United States.
Yajing LianPfizer Research & Development, Groton, Connecticut 06340, United States.
Wei LiuPfizer Research & Development, La Jolla, California 92121, United States.
Luis A Martínez AlsinaPfizer Research & Development, Groton, Connecticut 06340, United States.
Stephen NoellPfizer Research & Development, Groton, Connecticut 06340, United States.
R Scott ObachPfizer Research & Development, Groton, Connecticut 06340, United States.
Dafydd R OwenPfizer Research & Development, Cambridge, Massachusetts 02139, United States.ORCID 0000-0003-3106-7809
Nandini C PatelPfizer Research & Development, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-2735-7662
Devendra K RaiPfizer Research & Development, Groton, Connecticut 06340, United States.
Matthew R ReesePfizer Research & Development, Groton, Connecticut 06340, United States.
Hussin A RothanPfizer Research & Development, Pearl River, New York 10965, United States.
Sylvie SakataPfizer Research & Development, La Jolla, California 92121, United States.
Matthew F SammonsPfizer Research & Development, Cambridge, Massachusetts 02139, United States.ORCID 0000-0001-6472-0646
Jean G SathishPfizer Research & Development, Pearl River, New York 10965, United States.
Raman SharmaPfizer Research & Development, Groton, Connecticut 06340, United States.
Claire M SteppanPfizer Research & Development, Groton, Connecticut 06340, United States.
Jamison B TuttlePfizer Research & Development, Cambridge, Massachusetts 02139, United States.
Patrick R VerhoestPfizer Research & Development, Cambridge, Massachusetts 02139, United States.
Liuqing WeiPfizer Research & Development, Groton, Connecticut 06340, United States.
Qingyi YangPfizer Research & Development, Cambridge, Massachusetts 02139, United States.ORCID 0000-0001-5269-0494
Irina YurgelonisPfizer Research & Development, Pearl River, New York 10965, United States.
Yuao ZhuPfizer Research & Development, Pearl River, New York 10965, United States.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the record-breaking discovery, development and approval of vaccines and antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth leading cause of death in the world and third highest in the United States in 2022. Here, we report the discovery and characterization of PF-07817883, a second-generation, orally bioavailable, SARS-CoV-2 main protease inhibitor with improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid. We demonstrate the
Indexed as
Antiviral AgentsCOVID-19 Drug TreatmentProtease InhibitorsSARS-CoV-2Administration, OralAnimalsCoronavirus 3C ProteasesCOVID-19HumansMiceRatsAntiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.